Literature DB >> 23399585

Management of gestational hypertension - the impact of HYPITATa.

Jaimey M Pauli1, Julianne R Lauring, Christy M Stetter, John T Repke, John J Botti, Serdar H Ural, Anthony Ambrose.   

Abstract

AIMS: The objective of this study was to examine the impact of one trial (the HYPITAT trial) on management of gestational hypertension. STUDY
DESIGN: This is a retrospective cohort study of 5077 patients delivered at our institution from 7/1/2008 to 6/15/2011. "Pre-HYPITAT" was defined as 7/1/2008-9/30/2009 and "Post-HYPITAT" as 10/1/2009-6/15/2011. The primary outcome is the rate of delivery intervention for gestational hypertension. Secondary maternal and neonatal outcomes were analyzed in patients with gestational hypertension only. Statistical analyses included the χ2-test, Fisher's exact test, and the two-sample t-test.
RESULTS: The rate of delivery intervention Pre-HYPITAT was 1.9%, compared to 4% Post-HYPITAT (P<0.001). There was no significant change in secondary outcomes.
CONCLUSION: There was a statistically significant increase in delivery intervention for gestational hypertension at our institution after the publication of the HYPITAT trial. There was no significant change in immediate maternal or neonatal outcomes for patients with gestational hypertension.

Entities:  

Mesh:

Year:  2013        PMID: 23399585     DOI: 10.1515/jpm-2012-0179

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  2 in total

Review 1.  Pre-eclampsia part 2: prediction, prevention and management.

Authors:  Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Steven J Korzeniewski; Lami Yeo; Roberto Romero
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

2.  Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway.

Authors:  Xudong Zhao; Xietong Wang
Journal:  Mol Med Rep       Date:  2018-05-23       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.